Pages that link to "Q34107470"

The following pages link to Pharmacological options for the treatment of Tourette's disorder. (Q34107470):

Displaying 15 items.

• Neuropsychiatric consequences of cardiovascular medications (Q24635624) (← links)
• Fragile X syndrome: A review of clinical management (Q28076950) (← links)
• Animal models of tic disorders: a translational perspective (Q30395243) (← links)
• Mice repeatedly exposed to Group-A β-Haemolytic Streptococcus show perseverative behaviors, impaired sensorimotor gating, and immune activation in rostral diencephalon (Q30404423) (← links)
• Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome (Q30494205) (← links)
• Emerging drugs in Tourette syndrome (Q34423658) (← links)
• Tetrabenazine in the treatment of Huntington's disease (Q34606748) (← links)
• Tic disorders: from pathophysiology to treatment (Q36332445) (← links)
• The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement (Q37005139) (← links)
• Neurosurgical strategies for Gilles de la Tourette's syndrome (Q37106950) (← links)
• Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders (Q37589039) (← links)
• Aripiprazole for the treatment of adolescent Tourette's syndrome: a case report (Q37867282) (← links)
• Tourette syndrome increases risk of bone fractures: a population-based cohort study (Q39221933) (← links)
• The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. (Q47624983) (← links)
• Outpatient Treatment of Tic Disorders Among Children and Adults (Q92583479) (← links)